NEW YORK, Nov. 15, 2016 /PRNewswire/ -- Harwood Feffer LLP
(www.hfesq.com) is investigating potential claims against the board
of directors of ProNAi Therapeutics, Inc. ("ProNAi" or the
"Company") (NASDAQ: DNAI), concerning whether the board has
breached its fiduciary duties to shareholders.
ProNAi's product candidate, PNT2258, was designed to
lymphoma. During 2015 and 2016, the Company made consistent
public statements touting the efficacy of PNT2258. However,
on June 6, 2016, the Company was
forced to admit that PNT2258 had not shown sufficient efficacy to
justify continued research and studies of the drug would be
suspended. On this news, ProNAi stock lost approximately
two-thirds of its value.
Our investigation concerns whether the Company board of
directors has breached its fiduciary duties to shareholders,
grossly mismanaged the Company, and/or committed abuses of control
in connection with the foregoing.
If you own ProNAi shares and wish to discuss this matter with
us, or have any questions concerning your rights and interests with
regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the
firm.
Attorney Advertising. The law firm responsible for this
advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results
do not guarantee or predict a similar outcome with respect to any
future matter.
Logo -
http://photos.prnewswire.com/prnh/20120215/MM54604LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-pronai-therapeutics-inc-300363567.html
SOURCE Harwood Feffer LLP